EKF Diagnostics Holdings
plc
("EKF",
the "Company", or the "Group")
Notice of Full Year Results
and Investor Presentation
EKF Diagnostics Holdings
plc (AIM: EKF), the AIM-listed global diagnostics
business, will announce its full year results for the year ended 31 December
2023, on Wednesday 20 March 2024.
Investor Presentation
Julian Baines, Executive Chair, and
Stephen Young, Chief Financial Officer, will be hosting a live
online presentation relating to the Full Year results via the
Investor Meet Company platform at 4:30pm on Wednesday 20 March
2024. The presentation is open to all existing and potential
shareholders.
Investors can sign up to Investor
Meet Company for free and register for the presentation
here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
Investors who already follow EKF on
the Investor Meet Company platform will automatically be
invited.
A recording of the presentation, a
PDF of the slides used, and responses to the Q&A session will
be available on the Investor Meet Company platform
afterwards.
EKF
Diagnostics Holdings plc
|
www.ekfdiagnostics.com
|
Julian Baines, Executive Chair /
Stephen Young, CFO
|
Tel:
+44 (0)29 2071
0570
|
|
|
Singer Capital Markets (Nominated
Adviser & Joint Broker)
|
Tel: +44
(0)20 7496 3000
|
Aubrey Powell / Oliver
Platts
|
|
|
|
Walbrook PR Limited
|
Tel: +44 (0)20 7933 8780
or ekf@walbrookpr.com
|
Paul McManus / Charlotte
Edgar
|
Mob: +44
(0)7980 541 893 / +44 (0)7884 664 686
|
|
|
| |
About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)
EKF is an AIM-listed global
diagnostics business focussed on:
· Point-of-Care
analysers in the key areas of Hematology and
Diabetes, as well as Central Laboratory products including clinical
chemistry reagents, analysers and centrifuges
· Life Sciences
services provide specialist manufacture of enzymes
and custom products for use in diagnostic, food and industrial
applications, as well as other higher value Contract Manufacturing
services
EKF has headquarters in Penarth
(near Cardiff) and operates five manufacturing sites across the US
and Germany, selling into over 120 countries world-wide.